Cluenex
Log inStart free
All stocks · Real Estate · Office REITs

Alexandria Real Estate Equities ARE

Alexandria Real Estate Equities scores weak on business quality (3.6 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$45.51Oct 9, 2026
Business qualityWeak
Next earningsOct 26, 2026
Insiders, 90 daysBuying

Why it matters

  1. What Alexandria Real Estate Equities does

    Alexandria Real Estate Equities owns and leases specialized life science laboratories and office spaces to pharmaceutical and biotechnology tenants. Rent payments from these research facilities form the core revenue stream.

  2. What it does best

    Alexandria dominates life science clusters with a gross margin of 68.0%, outperforming DOC at 58.1%. This specialized asset concentration creates high tenant switching costs given the complex laboratory infrastructure built into each location.

  3. The main risk

    Refinancing pressures create ongoing cash flow challenges as seen after securing a new $5 billion credit facility. With free cash flow at -$460M and heavy capital expenditures of $1.7B, debt reliance remains a critical vulnerability.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Operating margin stands at 18.3% while free cash flow margin is negative due to heavy capex spending. Profitability is compressing as net income hits -$1.0B, proving the business currently struggles to generate cash at scale.

MoatFair

The asset base locks in life science tenants who rely on purpose-built lab clusters. Its operating margin ranks in the 30th percentile of its sector, reflecting moderate pricing power within its niche.

GrowthSlow

Revenue fell 6.0% to $2.8B, dropping from $3.0B previously and reversing earlier gains. This decline places revenue growth in the bottom 5% of its sector, showing a clear top-line contraction.

Financial healthFair

Total debt sits at $12.4B against $549M in cash, with interest coverage at 2.1x meaning earnings barely outpace interest obligations. Free cash flow is negative at -$460M, and the balance sheet is softening.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

1 insider bought $480K on the open market. 2 sold $1.4M outside pre-planned sales.

Our sealed record on ARE

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is ARE a good business?

Alexandria Real Estate Equities scores weak on the Cluenex quality check (3.6 of 10), measured against its own industry. Profitability is weak, moat fair, growth slow and financial health fair.

Are insiders buying ARE?

In the last 90 days of SEC Form 4 filings: 1 insider bought $480K on the open market. 2 sold $1.4M outside pre-planned sales.

When does ARE report earnings?

Oct 26, 2026.

For members

See ARE today

  • Today's verdict on ARE, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Alexandria Real Estate Equities (ARE)”, https://cluenex.com/stocks/are/, data as of Oct 10, 2026.